ORAGENICS INC (OGEN) is a pre-revenue development-stage biopharmaceutical company with a balance sheet that is almost entirely composed of cash and near-cash assets. Under a liquidation lens as of March 31, 2026, the recovery picture is marginally positive but functionally precarious. Total assets of $7.49M are entirely current (100% liquidation haircut applies at book for cash; no PP&E, no goodwill, no intangibles on balance sheet). Cash and cash equivalents of $6.11M receive a 100% recovery; prepaid expenses and other current assets of $1.38M are substantially insurance premiums and R&D vendor advances — recoverable at perhaps 30-50 cents on the dollar in a wind-down, yielding estimated recovery of $0.4M-$0.7M on that line. Total tagged liabilities are $1.31M, comprising $1.25M accounts payable and accrued expenses and $56K residual insurance premium financing note (virtually fully amortized, maturing April 2026). No long-term debt, no operating lease obligations, and no pension obligations appear on the balance sheet. At face-value liabilities of $1.31M against a best-case liquidation asset pool of approximately $6.8M (cash at 100% plus partial prepaid recovery), equity recovery is positive in the narrow range of roughly $5.5M-$6.8M — a result driven entirely by the $6.1M cash position. This is a structurally fragile recovery posture: the company burns approximately $2.2M per quarter in operating cash, has an accumulated deficit of $228.8M, and has received a going concern qualification from its auditor. Management states the current cash position ($6.1M) is sufficient to fund operations only through December 31, 2026. The filing introduces two material capital structure complexities. First, 428,291 shares of Series H Convertible Preferred Stock remain outstanding; in liquidation, holders receive what they would receive if converted to common stock immediately prior — no liquidation preference in excess of conversion value — but the conversion price was reset to $1.00 per share in March 2026 due to anti-dilution provisions triggered by an advisory fee share issuance at $1.00. This reset materially increases potential dilution overhang: the 428,291 outstanding Series H shares are now convertible into approximately 10.7M common shares, and the 660,000 Series H Warrants (if exercised) would convert into approximately 16.5M additional common shares. Second, a post-period LOI to license CardioDialysis technology from Sigyn Therapeutics contemplates issuance of 3,250,000 shares of a new restricted preferred series — not yet consummated, no XBRL tag emitted, referenced in MD&A narrative only. On a QoQ basis, the key change from the December 31, 2025 period is the $4.0M maturity of a short-term certificate of deposit (proceeds from investing activities), which replenished cash from $4.40M at year-end to $6.11M at quarter-end. The prior quarter (Q1 2025) comparison shows the company relied on equity raises and debt draws for cash; the current quarter's cash increase is investment maturity-driven, not new capital formation. The short-term notes payable line dropped from $227K to $56K as insurance financing amortized. No new debt was incurred.
▼ Community Notes